Asundexian: Advancing Secondary Stroke Prevention Strategies

Created using ChatSlide

This lecture delves into the potential of Asundexian, an inhibitor targeting Factor XI, in reducing the risk of ischemic stroke and cardiovascular events among patients with a history of transient ischemic attacks (TIA). Employing a rigorous double-blind, placebo-controlled trial design involving over 12,000 patients, the study reveals Asundexian's efficacy in lowering stroke recurrence without elevating bleeding risks. The findings underscore its promise as a safe therapeutic option for...